Synapse - William Pao

Results (141)

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers

Journal Article

Yu, H. A.; Sima, C.; Feldman, D.; Liu, L. L.; Vaitheesvaran, B.; Cross, J.; Rudin, C. M.; Kris, M. G.; Pao, W.; Michor, F.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

Journal Article

Girard, N.; Sima, C. S.; Jackman, D. M.; Sequist, L. V.; Chen, H.; Yang, J. C. H.; Ji, H.; Waltman, B.; Rosell, R.; Taron, M.; more...
European Respiratory Journal (2012)

Fulltext@MSK | Save

Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Journal Article

Grommes, C.; Oxnard, G. R.; Kris, M. G.; Miller, V. A.; Pao, W.; Holodny, A. I.; Clarke, J. L.; Lassman, A. B.
Neuro-Oncology (2011)

Fulltext@MSK | Save

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

Journal Article

Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Sima, C. S.; Kass, S. L.; Riely, G. J.; Pao, W.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations

Journal Article

Riely, G. J.; Johnson, M. L.; Medina, C.; Rizvi, N. A.; Miller, V. A.; Kris, M. G.; Pietanza, M. C.; Azzoli, C. G.; Krug, L. M.; Pao, W.; more...
Journal of Thoracic Oncology (2011)

Fulltext@MSK | Save

Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

Journal Article

Rizvi, N. A.; Rusch, V.; Pao, W.; Chaft, J. E.; Ladanyi, M.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Bains, M.; Downey, R.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation

Journal Article

Oxnard, G. R.; Arcila, M. E.; Sima, C. S.; Riely, G. J.; Chmielecki, J.; Kris, M. G.; Pao, W.; Ladanyi, M.; Miller, V. A.
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib

Journal Article

Janjigian, Y. Y.; Azzoli, C. G.; Krug, L. M.; Pereira, L. K.; Rizvi, N. A.; Pietanza, M. C.; Kris, M. G.; Ginsberg, M. S.; Pao, W.; Miller, V. A.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

Journal Article

Arcila, M. E.; Oxnard, G. R.; Nafa, K.; Riely, G. J.; Solomon, S. B.; Zakowski, M. F.; Kris, M. G.; Pao, W.; Miller, V. A.; Ladanyi, M.
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

Meeting Abstract

Yeo, W.; Riely, G. J.; Yeap, B.; Lau, M. W.; Warner, J.; Bodio, K. A.; Kris, M. G.; Pao, W.; Kobayashi, S.; Costa, D. B.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save